2. Cell Cycle/DNA Damage Cytoskeleton
  3. Microtubule/Tubulin
  4. Tau-aggregation and neuroinflammation-IN-1

Tau-aggregation and neuroinflammation-IN-1 

Cat. No.: HY-146005 Purity: 99.97%
Data Sheet
SDS
COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

Help & FAQs

Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats.

For research use only. We do not sell to patients.

Tau-aggregation and neuroinflammation-IN-1 Chemical Structure

Tau-aggregation and neuroinflammation-IN-1 Chemical Structure

CAS No. : 2175953-98-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 48 In-stock
Solution
10 mM * 1 mL in DMSO USD 51 In-stock
Solid
5 mg USD 50 In-stock
10 mg USD 80 In-stock
25 mg USD 150 In-stock
50 mg USD 240 In-stock
100 mg   Get quote  
200 mg   Get quote  

Get it by April 21 for select sizes. Order within 15 hrs 8 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats[1].

IC50 & Target

AcPHF6, tau-aggregation, NO[1]
In Vitro

Tau-aggregation and neuroinflammation-IN-1 (compound 30) (0-40 μM) reduces the survival of SH-SY5Y cells at 30 μM, and exerts no significant hepatotoxicity in LO2 cells at high concentrations, also exerts no effect on BV2 cell viability at 20 μM[1].
Tau-aggregation and neuroinflammation-IN-1 (2.5, 5 and 10 μM; 24 hours) retains the anti-inflammatory activity of sodium usnate and inhibits NO release rate by 41% in LPS-stimulated BV2 cells at 10 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line: SH-SY5Y, LO2 and BV-2 cells[1]
Concentration: 0, 10, 20, 30 and 40 μM
Incubation Time: 24 hours
Result: Reduced the survival of SH-SY5Y cells at 30 μM, and exerted no significant hepatotoxicity in LO2 cells even at high concentrations (up to 40 μM), also exerted no effect on BV2 cell viability at 20 μM.
In Vivo

Tau-aggregation and neuroinflammation-IN-1 (5 and 10 mg/kg; for 14 days) leads to a substantial improvement of the conventional reference spatial memory and cognitive abilities of OA-induced rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SD rats (250-270 g; OA was microinjected into the right dorsal hippocampus)[1]
Dosage: 5 and 10 mg/kg
Administration: IP; for 7 days, and after OA-injection continued IP for 7 days
Result: Led to a substantial improvement of the conventional reference spatial memory and cognitive abilities of rats.
Molecular Weight

460.44

Formula

C25H20N2O7
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(O)C1=CC=C(N2N=C(C)C3=C2C=C(OC4=C(C(C)=O)C(O)=C(C)C(O)=C45)[C@]5(C)C3=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (271.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1718 mL 10.8592 mL 21.7184 mL
5 mM 0.4344 mL 2.1718 mL 4.3437 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Purity & Documentation

Purity: 99.97%

Data Sheet (279 KB) SDS (393 KB)

COA (258 KB) HNMR (264 KB) LCMS (93 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1718 mL 10.8592 mL 21.7184 mL 54.2959 mL
5 mM 0.4344 mL 2.1718 mL 4.3437 mL 10.8592 mL
10 mM 0.2172 mL 1.0859 mL 2.1718 mL 5.4296 mL
15 mM 0.1448 mL 0.7239 mL 1.4479 mL 3.6197 mL
20 mM 0.1086 mL 0.5430 mL 1.0859 mL 2.7148 mL
25 mM 0.0869 mL 0.4344 mL 0.8687 mL 2.1718 mL
30 mM 0.0724 mL 0.3620 mL 0.7239 mL 1.8099 mL
40 mM 0.0543 mL 0.2715 mL 0.5430 mL 1.3574 mL
50 mM 0.0434 mL 0.2172 mL 0.4344 mL 1.0859 mL
60 mM 0.0362 mL 0.1810 mL 0.3620 mL 0.9049 mL
80 mM 0.0271 mL 0.1357 mL 0.2715 mL 0.6787 mL
100 mM 0.0217 mL 0.1086 mL 0.2172 mL 0.5430 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tau-aggregation and neuroinflammation-IN-1 Related Classifications

Help & FAQs
  • How should lyophilized recombinant proteins be reconstituted and stored?

    1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss. 2. Taking 10 μg as an example, first add 20 μL of reconstituted solution provided by MCE and use a pipette to gently resuspend the lyophilized protein until it is fully dissolved.. (For most proteins, the reconstitution solution we provide is sterile water. If a diluent other than water is required, it will be indicated in the product's Certificate of Analysis (COA).). 3. Add an additional 80 μL of buffer/culture medium containing carrier protein (either 0.1% BSA, 5% HSA, 10% FBS, or 5% trehalose), and then use a pipette to gently mix until uniform. The final concentration is should not be lower than 100 μg/mL. 4. Aliquot at least 20 μL per tube. 5. After aliquoting, store it frozen at a temperature ranging from -20ºC to -80ºC, and it can be preserved for 3 to 6 months.

  • How should solution-form recombinant proteins be stored?

    1. The product can be stored in its original form and diluted as needed upon use. 2. Alternatively, dilute with a buffer/culture medium containing a carrier protein (either 0.1% BSA, 5% HSA, 10% FBS, or 5% alginate), mix well by pipetting, and ensure that

  • Why is it necessary to add carrier proteins?

    Carrier proteins are commonly added to enhance the stability of recombinant proteins, preventing them from adhering to the walls of the container during freezing or thawing processes. Plastic tubes have a certain adsorptive capacity for proteins, which may lead to difficulty in separating the protein from the tube walls, resulting in a decrease in the actual concentration of the protein in the solution and thus affecting its activity. To minimize such losses, it is recommended to add a commonly used carrier protein solution prior to the long-term storage of recombinant protein products.

  • Carrier protein types and options?

    In cases where the carrier protein is not expected to influence the experimental outcomes, an appropriate carrier protein, such as 0.1% BSA (Bovine Serum Albumin), 5% HSA (Human Serum Albumin), 10% FBS (Fetal Bovine Serum), or 5% trehalose, can be incorpo

Keywords:

Tau-aggregation and neuroinflammation-IN-12175953-98-5Microtubule/TubulinUsnic acid derivativesAlzheimer’s diseaseTau anti-aggregationAnti-inflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tau-aggregation and neuroinflammation-IN-1
Cat. No.:
HY-146005
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.